117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 213
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Mondher Mahjoubi M.D. | Chairman of Exec. Board & CEO | 1,05M | S.O. | 1958 |
Mr. Yannis Morel Ph.D. | Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board | 415,85k | S.O. | 1973 |
Dr. Herve Brailly | Co-Founder & Chairman of Supervisory Board | S.O. | S.O. | 1961 |
Dr. François Romagné Ph.D. | Founder | S.O. | S.O. | 1964 |
Mr. Eric Vivier D.V.M., M.B.A., Ph.D. | Founder, Sr. VP & Chief Scientific Officer | S.O. | S.O. | 1964 |
Dr. Marc Bonneville Ph.D. | Founder | S.O. | S.O. | 1960 |
Mr. Jean Jacques Fournié Ph.D. | Founder | S.O. | S.O. | S.O. |
Mr. Alessandro Moretta M.D., Ph.D. | Founder | S.O. | S.O. | S.O. |
Mr. Frederic Lombard M.B.A. | Sr. VP & CFO | S.O. | S.O. | 1975 |
Ms. Odile Belzunce | VP of Compliance & Operations | S.O. | S.O. | 1980 |
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
L’ISS Governance QualityScore de Innate Pharma S.A. en date du 1 février 2023 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 1; Compensation : 10.